Odyssey Therapeutics Inc ODTX

$16.96 -1.38 (-7.52%)

Valuation

Market cap
881,567,000
Revenue TTM
$2,976,000
Net income TTM
$-148,647,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-4,994.86%
Debt to equity
0.00

Trading

Volume
677,800
Avg volume
368,044
Day's range
$16.46 – $18.08
Shares out
48,068,000
Stochastic %K
11%
Beta
—
Analysts
Strong Buy
Price target
$34.67

Price

Company profile

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammato...

Show more

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 865 9628
Website
https://odysseytx.com
Address
51 Sleeper Street, Suite 800, Boston, United States

Latest news

No headlines yet.